140 related articles for article (PubMed ID: 10748176)
21. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
[TBL] [Abstract][Full Text] [Related]
22. Tumour suppression by the human von Hippel-Lindau gene product.
Iliopoulos O; Kibel A; Gray S; Kaelin WG
Nat Med; 1995 Aug; 1(8):822-6. PubMed ID: 7585187
[TBL] [Abstract][Full Text] [Related]
23. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association.
Cohen HT; Zhou M; Welsh AM; Zarghamee S; Scholz H; Mukhopadhyay D; Kishida T; Zbar B; Knebelmann B; Sukhatme VP
Biochem Biophys Res Commun; 1999 Dec; 266(1):43-50. PubMed ID: 10581162
[TBL] [Abstract][Full Text] [Related]
24. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
25. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
26. Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking.
Kim DS; Choi YB; Han BG; Park SY; Jeon Y; Kim DH; Ahn ER; Shin JE; Lee BI; Lee H; Hong KM; Kim SY
Oncogene; 2011 Dec; 30(48):4780-90. PubMed ID: 21625219
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
28. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
29. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
30. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Ivanova AV; Ivanov SV; Danilkovitch-Miagkova A; Lerman MI
J Biol Chem; 2001 May; 276(18):15306-15. PubMed ID: 11278694
[TBL] [Abstract][Full Text] [Related]
31. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Los M; Zeamari S; Foekens JA; Gebbink MF; Voest EE
Cancer Res; 1999 Sep; 59(17):4440-5. PubMed ID: 10485495
[TBL] [Abstract][Full Text] [Related]
32. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
33. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes.
Okuda H; Hirai S; Takaki Y; Kamada M; Baba M; Sakai N; Kishida T; Kaneko S; Yao M; Ohno S; Shuin T
Biochem Biophys Res Commun; 1999 Sep; 263(2):491-7. PubMed ID: 10491320
[TBL] [Abstract][Full Text] [Related]
34. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
35. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.
Currie MJ; Gunningham SP; Turner K; Han C; Scott PA; Robinson BA; Chong W; Harris AL; Fox SB
J Pathol; 2002 Dec; 198(4):502-10. PubMed ID: 12434420
[TBL] [Abstract][Full Text] [Related]
36. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes.
Ivanov SV; Kuzmin I; Wei MH; Pack S; Geil L; Johnson BE; Stanbridge EJ; Lerman MI
Proc Natl Acad Sci U S A; 1998 Oct; 95(21):12596-601. PubMed ID: 9770531
[TBL] [Abstract][Full Text] [Related]
38. Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility.
Hsu T; Adereth Y; Kose N; Dammai V
J Biol Chem; 2006 Apr; 281(17):12069-80. PubMed ID: 16505488
[TBL] [Abstract][Full Text] [Related]
39. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
An J; Rettig MB
Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
